Published in Biomark Med on June 01, 2012
Clinical implementation of germ line cancer pharmacogenetic variants during the next-generation sequencing era. Clin Pharmacol Ther (2013) 1.10
Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment. J Clin Pharmacol (2016) 0.77
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (2007) 25.52
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med (2007) 20.19
SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap. Bioinformatics (2008) 15.77
Treatment of acute lymphoblastic leukemia. N Engl J Med (2006) 11.30
CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther (2011) 10.95
Pharmacogenomics--drug disposition, drug targets, and side effects. N Engl J Med (2003) 7.23
Regression modeling of competing risks data based on pseudovalues of the cumulative incidence function. Biometrics (2005) 6.45
Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther (2011) 5.44
Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol (2008) 5.28
Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. J Clin Oncol (2004) 5.08
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol (2004) 5.06
Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst (2009) 4.36
Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood (2004) 4.21
Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol (2005) 4.02
UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst (2007) 3.85
Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol (2006) 3.59
Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst (1999) 3.58
Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci U S A (1998) 3.56
Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol (2008) 3.53
Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis (2007) 3.47
Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood (2009) 3.47
Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS One (2009) 3.45
Pharmacogenetics: from bench to byte--an update of guidelines. Clin Pharmacol Ther (2011) 3.36
Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat (2010) 3.35
Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res (2007) 3.18
Moving towards individualized medicine with pharmacogenomics. Nature (2004) 2.99
Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clin Cancer Res (2006) 2.84
Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest (1998) 2.62
Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse. Clin Cancer Res (2010) 2.56
Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin Cancer Res (2011) 2.52
CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer (2009) 2.32
Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J Clin Oncol (2006) 2.32
Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer (2005) 2.25
Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J Pediatr (1991) 2.24
Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer (2006) 2.11
Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. Leukemia (2009) 2.11
Dose selection in phase I studies: why we should always go for the top. J Clin Oncol (2008) 2.08
Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol (2009) 2.06
Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol (1998) 2.05
Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients. Clin Cancer Res (2005) 1.98
Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther (1999) 1.94
Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol (2010) 1.93
Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol (2008) 1.91
Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. Clin Colorectal Cancer (2006) 1.83
Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin Pharmacol Ther (2008) 1.82
Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood (2005) 1.80
UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer (2004) 1.73
Impact of chemotherapy dose intensity on cancer patient outcomes. J Natl Compr Canc Netw (2009) 1.63
An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res (2004) 1.55
Risk of adverse events after completion of therapy for childhood acute lymphoblastic leukemia. J Clin Oncol (2005) 1.53
Thiopurine methyltransferase in acute lymphoblastic leukemia. Blood (2006) 1.52
Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood (2007) 1.52
Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens (2010) 1.50
Oral methotrexate/6-mercaptopurine may be superior to a multidrug LSA2L2 Maintenance therapy for higher risk childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. J Pediatr Hematol Oncol (2009) 1.44
Drug methylation in cancer therapy: lessons from the TPMT polymorphism. Oncogene (2003) 1.40
Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers. Arch Intern Med (2007) 1.34
Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with colorectal cancer. Clin Cancer Res (2008) 1.32
Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. J Clin Oncol (2009) 1.28
Pharmacogenomics: from bedside to clinical practice. Hum Mol Genet (2006) 1.28
High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics (2002) 1.21
UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma. Cancer (2008) 1.20
Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment. Pharmacogenomics (2009) 1.18
Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms. Cancer Sci (2011) 1.17
Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy. Cancer (2006) 1.16
A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer. Br J Cancer (2011) 1.15
Dose-dependent association between UGT1A1*28 genotype and irinotecan-induced neutropenia: low doses also increase risk. Clin Cancer Res (2010) 1.14
Germline genetic variation, cancer outcome, and pharmacogenetics. J Clin Oncol (2010) 1.12
Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping. Pharmacogenomics (2006) 1.11
Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation. Int J Cancer (2002) 1.09
Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status. Expert Opin Drug Saf (2010) 1.08
The role of pharmacogenetics in cancer therapeutics. Br J Clin Pharmacol (2006) 1.06
Chemotherapy dosing part I: scientific basis for current practice and use of body surface area. Clin Oncol (R Coll Radiol) (2007) 1.04
Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients. Cancer (2011) 1.03
Common polymorphisms in the vascular endothelial growth factor gene and colorectal cancer development, prognosis, and survival. Mol Carcinog (2009) 1.02
Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib. Pharmacogenomics J (2007) 1.01
Erlotinib 'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer. Br J Cancer (2011) 0.99
Translating the cancer genome into clinically useful tools and strategies. Dis Model Mech (2009) 0.98
Hepatocyte nuclear factor-1 alpha is associated with UGT1A1, UGT1A9 and UGT2B7 mRNA expression in human liver. Pharmacogenomics J (2007) 0.97
Erlotinib-induced skin rash. Pathogenesis, clinical significance and management in pancreatic cancer patients. JOP (2008) 0.97
Expression and inducibility of the human bilirubin UDP-glucuronosyltransferase UGT1A1 in liver and cultured primary hepatocytes: evidence for both genetic and environmental influences. Hepatology (1999) 0.94
EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment. Lung Cancer (2008) 0.94
Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer. BMC Cancer (2011) 0.94
Risk of high-grade skin rash in cancer patients treated with cetuximab--an antibody against epidermal growth factor receptor: systemic review and meta-analysis. Oncology (2009) 0.94
Germline polymorphisms in EGFR and survival in patients with lung cancer receiving gefitinib. Clin Pharmacol Ther (2007) 0.94
Variants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase and thymidylate synthase genes predict early toxicity of 5-fluorouracil in colorectal cancer patients. J Int Med Res (2010) 0.92
The epidermal growth factor receptor intron1 (CA) n microsatellite polymorphism is a potential predictor of treatment outcome in patients with advanced lung cancer treated with Gefitinib. Eur J Pharmacol (2007) 0.92
Dose selection in phase I studies: why we should always go for the most effective. J Clin Oncol (2008) 0.90
TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy? Trends Pharmacol Sci (2006) 0.89
Cancer pharmacogenomics. Clin Pharmacol Ther (2011) 0.89
Pharmacogenomic contribution to drug response. Cancer J (2011) 0.86
The Importance of Planned Dose of Chemotherapy on Time: Do We Need to Change Our Clinical Practice? Oncologist (1998) 0.85
The use of genomic information to optimize cancer chemotherapy. Semin Oncol (2011) 0.84
Methylation of the DPYD promoter and dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res (2006) 0.84
Meta-analysis of docetaxel-based doublet versus docetaxel alone as second-line treatment for advanced non-small-cell lung cancer. Cancer Chemother Pharmacol (2011) 0.84
A reporting system for the assessment of chemotherapy toxicity. J Oncol Pharm Pract (2005) 0.84
Use of pyrosequencing to detect clinically relevant polymorphisms in dihydropyrimidine dehydrogenase. Clin Chem (2003) 0.83
Suppression of DPYD expression in RKO cells via DNA methylation in the regulatory region of the DPYD promoter: a potentially important epigenetic mechanism regulating DPYD expression. Biochem Cell Biol (2007) 0.83
Systematic review of thiopurine methyltransferase genotype and enzymatic testing strategies. Ther Drug Monit (2011) 0.82
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol (2010) 5.21
Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. J Clin Oncol (2009) 2.40
Ethnic differences and functional analysis of MET mutations in lung cancer. Clin Cancer Res (2009) 2.03
A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. Cancer Res (2005) 1.62
Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism. Clin Cancer Res (2003) 1.37
A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine. Clin Pharmacol Ther (2003) 1.31
Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. J Clin Oncol (2009) 1.28
Clinical pharmacology and pharmacogenetics of gemcitabine. Drug Metab Rev (2009) 1.27
Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines. Clin Cancer Res (2007) 1.20
Insights, challenges, and future directions in irinogenetics. Ther Drug Monit (2007) 1.17
The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity. J Clin Pharmacol (2007) 1.16
Effect of methylenetetrahydrofolate reductase 677C-->T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients. Int J Cancer (2003) 1.08
UGT pharmacogenomics: implications for cancer risk and cancer therapeutics. Pharmacogenetics (2003) 1.07
The role of pharmacogenetics in cancer therapeutics. Br J Clin Pharmacol (2006) 1.06
Searching for tissue-specific expression pattern-linked nucleotides of UGT1A isoforms. PLoS One (2007) 1.05
Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer. Clin Cancer Res (2011) 1.05
Translating the cancer genome into clinically useful tools and strategies. Dis Model Mech (2009) 0.98
Implications of genome-wide association studies in cancer therapeutics. Br J Clin Pharmacol (2013) 0.96
Effects of ketoconazole on glucuronidation by UDP-glucuronosyltransferase enzymes. Clin Cancer Res (2005) 0.95
A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours. Eur J Cancer (2008) 0.94
Lack of association between common polymorphisms in UGT1A9 and gene expression and activity. Drug Metab Dispos (2007) 0.93
In vitro characterization of hepatic flavopiridol metabolism using human liver microsomes and recombinant UGT enzymes. Pharm Res (2002) 0.93
A genome-wide integrative study of microRNAs in human liver. BMC Genomics (2013) 0.92
Irinogenetics: what is the right star? J Clin Oncol (2006) 0.91
Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens. J Pharmacol Exp Ther (2013) 0.91
Pharmacogenomics: road to anticancer therapeutics nirvana? Oncogene (2003) 0.90
Discovery and functional assessment of gene variants in the vascular endothelial growth factor pathway. Hum Mutat (2013) 0.89
UGT1A1*28 genotype affects the in-vitro glucuronidation of thyroxine in human livers. Pharmacogenet Genomics (2007) 0.88
Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet? Pharmacotherapy (2008) 0.88
Mechanisms of genetic regulation in gene expression: examples from drug metabolizing enzymes and transporters. Wiley Interdiscip Rev Syst Biol Med (2010) 0.87
CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes. Drug Metab Dispos (2004) 0.86
Individualizing dosing of irinotecan. Clin Cancer Res (2010) 0.86
Systemic therapies for pancreatic cancer--the role of pharmacogenetics. Curr Drug Targets (2012) 0.86
Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer. Cancer Chemother Pharmacol (2007) 0.84
Study of the genetic determinants of UGT1A1 inducibility by phenobarbital in cultured human hepatocytes. Pharmacogenet Genomics (2006) 0.84
Pharmacogenomics: paving the path to personalized medicine. Pharmacogenomics (2010) 0.84
The influence of UGT polymorphisms as biomarkers in solid organ transplantation. Clin Chim Acta (2012) 0.83
Institutional Profile: Golden Helix Institute of Biomedical Research: interdisciplinary research and educational activities in pharmacogenomics and personalized medicine. Pharmacogenomics (2012) 0.82
Liver expression quantitative trait loci: a foundation for pharmacogenomic research. Front Genet (2012) 0.82
A guide to the current Web-based resources in pharmacogenomics. Methods Mol Biol (2013) 0.81
Functional FLT1 Genetic Variation is a Prognostic Factor for Recurrence in Stage I-III Non-Small-Cell Lung Cancer. J Thorac Oncol (2015) 0.81
Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy. Future Oncol (2010) 0.80
Genetic Analysis in Translational Medicine: The 2010 GOLDEN HELIX Symposium. Hum Mutat (2011) 0.80
Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients. Br J Clin Pharmacol (2002) 0.80
Architecture of pharmacogenomic associations: structures with functional foundations or castles made of sand? Pharmacogenomics (2013) 0.79
Translation of pharmacogenetic knowledge into cancer therapeutics. Clin Adv Hematol Oncol (2007) 0.78
Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan. Pharmacogenomics (2009) 0.78
The effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patients. Cancer Chemother Pharmacol (2011) 0.77
Genomics into Healthcare: the 5th Pan Arab Human Genetics Conference and 2013 Golden Helix Symposium. Hum Mutat (2014) 0.77
Linkage disequilibrium across the UGT1A locus should not be ignored in association studies of cancer susceptibility. Clin Cancer Res (2005) 0.77
A phase I trial of pharmacokinetic modulation of carboxyamidotriazole (CAI) with ketoconazole in patients with advanced cancer. Cancer Chemother Pharmacol (2004) 0.77
Effects of green tea compounds on irinotecan metabolism. Drug Metab Dispos (2006) 0.76
Recent progress and clinical importance on pharmacogenetics in cancer therapy. Clin Chem Lab Med (2011) 0.76
MTHFR and ALL risk: a challenge. Leuk Lymphoma (2006) 0.75
R(+)XK469 inhibits hydroxylation of S-warfarin by CYP2C9. Eur J Cancer (2009) 0.75
A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469. Pharmacogenet Genomics (2014) 0.75
Test Pricing and Reimbursement in Genomic Medicine: Towards a General Strategy. Public Health Genomics (2016) 0.75
ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients. Pharmacogenet Genomics (2015) 0.75